Raising the Bar: High Time in Range During the First Year of Diagnosis of Type 1 Diabetes in Children and Adolescents Using Automated Insulin Delivery with Intense Support
Restricted accessLetterFirst published online 2026
Raising the Bar: High Time in Range During the First Year of Diagnosis of Type 1 Diabetes in Children and Adolescents Using Automated Insulin Delivery with Intense Support
BoughtonCK, AllenJM, WareJ, et al.; CLOuD Consortium. Closed-Loop therapy and preservation of c-peptide secretion in type 1 diabetes. N Engl J Med, 2022; 387(10):882–893; doi: 10.1056/NEJMoa2203496
2.
McVeanJ, ForlenzaGP, BeckRW, et al.; CLVer Study Group. Effect of tight glycemic control on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: A randomized clinical trial. JAMA: The Journal of the American Medical Association, 2023; 329(12):980–989; doi: 10.1001/jama.2023.2063
3.
RamosEL, DayanCM, ChatenoudL, et al.; PROTECT Study Investigators. Teplizumab and beta-Cell function in newly diagnosed type 1 diabetes. N Engl J Med, 2023; 389(23):2151–2161; doi: 10.1056/NEJMoa230874320231018
4.
AyeT, BoneyCM, OrrCJ, et al.Child health needs and the pediatric endocrinology workforce: 2020–2040. Pediatrics, 2024; 153(Suppl 2):e2023063678J; doi: 10.1542/peds.2023-063678J
5.
PrahaladP, DingVY, ZaharievaDP, et al.Teamwork, targets, technology, and tight control in newly diagnosed type 1 diabetes: The Pilot 4T Study. J Clin Endocrinol Metab, 2022; 107(4):998–1008; doi: 10.1210/clinem/dgab859
